Keywords: Belysta, Lupus, Human Genome, GlaxoSmithKline, Decision Resources

Benlysta continues to penetrate lupus market one year post-launch; report

Article | 08 May 2012

Print This

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and Human Genome Science’s (Nasdaq: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in